Production suspension of a batch of drugs (list attached)

On January 8, Hainan Provincial Pharmaceutical centralized purchasing center issued the notice on publicizing the withdrawal of some drugs from the Internet (January 8, 2020), and 250 drugs applied for withdrawal of the Internet According to the notice, these are the drug withdrawal applications accepted since April 2019 The publicity period is from January 8, 2020 to January 14, 2020 After the expiration of the publicity period, the drugs without objection will be removed from the Internet In this application, there are 250 drugs in total, 171 of which are shut down due to rising production cost, abnormal supply, production line transformation, production line stop and other reasons, 28 of which are shut down due to rising price or shortage of APIs, and 15 of which are shut down due to price and cost inversion According to the notice, 28 drugs such as ligustrazine hydrochloride injection, Banlangen Granules, zaleplon, alprazolam, methimazole tablets, m-hydroxyamine heavy tartrate injection and vitamin K1 injection cannot be guaranteed due to the rising price of raw materials These products with rising API prices have obvious characteristics For example, Banlangen Granule is a traditional Chinese medicine for anti influenza, especially in the flu season, which is in great demand; the injection of m-hydroxyamine tartrate and vitamin K1 is an emergency medicine, which has been in short supply for many times; methimazole tablet is a commonly used medicine for hyperthyroidism patients, and it is also a cheap medicine frequently in short supply and out of stock in recent years According to Ding Xiangyuan's insight database, the price of many first-aid drugs remained stable until 2013, and gradually increased after 2013 However, by 2018, the price of many first-aid drugs began to soar, with an increase of more than 10 times or even 70 times As for Chinese patent medicine, in recent years, due to the price rise of some Chinese herbal medicines, the state has tightened the quality control of Chinese herbal medicines, resulting in the increase of production costs According to relevant pharmaceutical companies, many cheap and high-quality drugs are out of stock due to the artificial control of raw materials, resulting in a large increase in the production cost of manufacturers without raw materials This is a common phenomenon in the pharmaceutical industry in recent two years The price of raw materials for drugs such as isoniazid and chlorpheniramine has risen from 2000 yuan per kilogram to 50000 yuan It is worth noting that 15 of the drugs in Hainan province that have been withdrawn from the Internet this time are due to the reverse hanging of the bid price and cost, resulting in the inability to continue production and supply As we all know, in recent years, the price of drugs has been squeezed more and more low under the policies of centralized drug purchase, belt purchase, GPO and other bidding policies In order to keep the market, some manufacturers are willing to fight a price war, which disrupts the price system of their products Under the national linkage mechanism of drug prices, they can not bear the pressure of low prices There are also some products, because the prices of production cost and raw material cost are constantly rising, but the price of drugs has not increased for more than ten years, or has been continuously depressed Once the bid price of drugs is overwhelmed below the cost price, the product will naturally not be able to stand on the market Although there may also be some benign governance factors, resulting in price increases, such as environmental protection, urbanization, and some disordered production before governance, resulting in some cost increases, but such increases are usually within the scope of 20% and 30%, which can be accepted by everyone, and the state is willing to give subsidies, so that manufacturers can basically maintain production and make reasonable profits In fact, the price and cost of drugs have long been paid attention to by the state Recently, a letter issued by the office of the State Medical Insurance Bureau on Soliciting Opinions on "notice on good drug price management at this stage" circulated in the industry, in which the price control mentioned: Relying on the centralized procurement of drugs at all provincial levels, the construction of the national drug public procurement market, the unified coding, standards and functional specifications, the promotion of information interconnection, resource sharing and policy linkage, the comprehensive use of monitoring and early warning, correspondence and interview, cost investigation, credit evaluation, information disclosure and other means, gradually improve the specific methods and methods, establish and improve the regulatory mechanism of drug price normalization In terms of supply assurance, as early as June 2017, the implementation opinions on reforming and improving the mechanism of supply assurance of short drugs jointly issued by the state health and Family Planning Commission and other nine departments proposed to establish a hierarchical linkage response mechanism for supply assurance of short drugs, and implement classified and precise measures for supply assurance of short drugs In the era of big data and information technology, drug price and cost inversion will be effectively avoided We hope that with the promotion of national medical reform and the gradual implementation of various policies to solve the problem of drug shortage, the problem of drug shortage can be truly solved and the price of drugs can be increasingly reasonable.